Inclusion Criteria:

- Signed Informed Consent Form

- Metastatic or locally advanced and unresectable CRC or locally advanced or metastatic
NSCLC (excluding predominant squamous histology)

- Eligible for Avastin as a component of intended therapy

- First-line chemotherapy (or second-line chemotherapy for CRC) plus Avastin initiated
≤ 4 months prior to study enrollment

Exclusion Criteria:

- Any medical condition, including mental illness or substance abuse, deemed by the
investigator to be likely to interfere with a patient's ability to provide informed
consent or comply with the treatment and follow-up, as specified by the investigator

- Enrollment in a blinded, placebo-controlled bevacizumab trial